DBL™ Vinorelbine Injection Concentrate Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

dbl™ vinorelbine injection concentrate

pfizer new zealand limited - vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine excipient: nitrogen water for injection - dbl™ vinorelbine injection concentrate is indicated as a single agent or in combination for 1. the treatment of non small cell lung cancer (nsclc), and 2. the second line treatment of advanced breast cancer.

Navelbine Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

navelbine

new zealand medical & scientific ltd - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg - soft gelatin capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide - first line treatment of advanced non-small cell lung cancer (nsclc) as a single agent or in combination

Navelbine Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

navelbine

new zealand medical & scientific ltd - vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg - soft gelatin capsule - 30 mg - active: vinorelbine tartrate 41.55mg equivalent to vinorelbine 30 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide red macrogol 400 medium-chain triglycerides purified water   titanium dioxide - first line treatment of advanced non-small cell lung cancer (nsclc) as a single agent or in combination

Navelbine Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

navelbine

new zealand medical & scientific ltd - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine - solution for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine excipient: water for injection

Vinorelbine Ebewe Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

vinorelbine ebewe

sandoz new zealand limited - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine excipient: water for injection - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first-line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

GLIVEC  100 MG Izrael - engleski - Ministry of Health

glivec 100 mg

novartis israel ltd - imatinib as mesylate - film coated tablets - imatinib as mesylate 100 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).glivec is also indicated for the treament of : * adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy.* adult patients with relapsed or refractory ph + all as monotherapy.* adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. * adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr (platelet - derived growth factor receptor ) gene re- arrangements. * adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) who have the fip1l1- pdgfralfa fusion kinase (mutational analysis or fish demonstration fo chic2 allele deletion) and for patients with hes and/or cel who are fip1l1-pdgfr alfa fusion kinase negative. * adult patients with aggressive systemic mastocytosis (asm) without the d816v c-kit mutation.* adjuvant treatment of adult patients following complete gross resection of kit (cd117) positive gist.

GLIVEC  400 MG Izrael - engleski - Ministry of Health

glivec 400 mg

novartis israel ltd - imatinib as mesylate - film coated tablets - imatinib as mesylate 400 mg - imatinib - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : * adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. * adult patients with relapsed or refractory ph + all as monotherapy. * adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. * adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr (platelet - derived growth factor receptor ) gene re- arrangements. * adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) who have the fip1l1- pdgfralfa fusion kinase (mutational analysis or fish demonstration for chic2 allele deletion) and for patients with hes and/or cel who are fip1l1-pdgfr alfa fusion kinase negative. * adult patients with aggressive systemic mastocytosis (asm) without the d816v c-kit mutation. * adjuvant treatment of adult patients following complete gross resection of kit (cd117) positive gist.

Mitomycin-C Kyowa 10 mg, Powder for Solution for Injection Irska - engleski - HPRA (Health Products Regulatory Authority)

mitomycin-c kyowa 10 mg, powder for solution for injection

kyowa kirin limited - mitomycin - powder for solution for injection - 10 milligram(s) - other cytotoxic antibiotics; mitomycin

Mitomycin-C Kyowa 40 mg, Powder for Solution for Injection Irska - engleski - HPRA (Health Products Regulatory Authority)

mitomycin-c kyowa 40 mg, powder for solution for injection

kyowa kirin limited - mitomycin - powder for solution for injection - 40 milligram(s) - other cytotoxic antibiotics; mitomycin